Study to evaluate immunogenicity and safety of three production lots of GSK Biologicals' combined MeMuRu-OKA candidate vaccine given on a two-dose schedule to healthy children in their second year of life, as compared to separate administration of GSK Biologicals' Priorix™ and Varilrix™ vaccines
Combined Measles, Mumps, Rubella, Varicella Vaccine
Measles; Mumps; Rubella; Varicella
Phase 3
Follow on studies 208136/039, 208136/040, and 208136/041 were conducted. An annotated case report form is not available for this study. A blank case report form will be provided. A link to and a NCT ID number are not available for this study because the study was conducted before regulatory requirements to register studies.
February 2015